Management of Bone Disease and Body Composition Changes
Summary
- Mulligan and colleagues[Mulligan 2009] published the results of a small, open-label, proof-of-concept study using recombinant human leptin in the treatment of 8 HIV-infected patients with lipoatrophy, hypoleptinemia, insulin resistance, and dyslipidemia
- 6 months of leptin treatment led to a significant (32%) decrease in visceral fat without significant effect on subcutaneous or peripheral fat deposits
- Significant improvements in hepatic insulin sensitivity, serum triglyceride concentrations, and in total, LDL, and non–HDL cholesterol concentrations were also found with leptin therapy
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content